ReviewFrontiers in microbiology2016
Aspergillus fumigatus-Related Species in Clinical Practice.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 179 citations in OpenAlex.
- Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Endobronchial Aspergillosis Presenting as an Isolated Airway Lesion in an Immunocompromised Patient.Respirology case reports · 2026Article
- Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update).Mycoses · 2026Review
- Opportunistic pathogenicity in fungi can transcend species boundaries.bioRxiv : the preprint server for biology · 2026Article
- Subtractive Proteomics and Immunoinformatics-Guided Design of a Multi-Epitope Vaccine Against Aspergillus fumigatus.Probiotics and antimicrobial proteins · 2026Article
- In Vitro and In Silico Investigations of Antifungal Activity of Ethyl Acetate Extracts of Various Species of Swertia Against Aspergillus fumigatus.Chemistry & biodiversity · 2026Article
- The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat.The Journal of antimicrobial chemotherapy · 2026Article
- Comparative Enzymology and Biomass Hydrolysis Reveal Industrial Biorefining Potential ofMicroorganisms · 2026Article
- Case report: intracranial fungal granuloma in a dromedary (Camelus dromedarius).BMC veterinary research · 2026Article
- Article
- BeyondAntimicrobial agents and chemotherapy · 2026Article
- Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistantAntimicrobial agents and chemotherapy · 2026Article
- Detection of TR34/L98H pan-azole-resistantFrontiers in fungal biology · 2026Article
- Genetic analysis of common triazole resistance mechanisms in a collection ofAntimicrobial agents and chemotherapy · 2025Article
- Agricultural SDHIs Induce Azole Resistance in Aspergillus fumigatus via Mitochondrial Sdh1 Suppression.Mycopathologia · 2025Article
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand.Mycoses · 2025Article
- Clinical aspects and recent advances in fungal diseases impacting human health.The Journal of antimicrobial chemotherapy · 2025Review
- Critical insights on fungal contamination in schools: a comprehensive review of assessment methods.Frontiers in public health · 2025Review
- Comparison of Morphological, Virulence, and Antifungal Susceptibility Characteristics WithinInfection and drug resistance · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus is the main etiologic agent of invasive aspergillosis (IA). Other Aspergillus species belonging to the section Fumigati (A. fumigatus complex) may occasionally be the cause of IA. These strains are often misidentified, as they cannot be distinguished from A. fumigatus by conventional morphological analysis and sequencing methods. This lack of recognition may have important consequences as these A. fumigatus-related species often display some level of intrinsic resistance to azoles and other antifungal drugs. A. lentulus, A. udagawae, A. viridinutans, and A. thermomutatus (Neosartorya pseudofischeri) have been associated with refractory cases of IA. Microbiologists should be able to suspect the presence of these cryptic species behind a putative A. fumigatus isolate on the basis of some simple characteristics, such as defect in sporulation and/or unusual antifungal susceptibility profile. However, definitive species identification requires specific sequencing analyses of the beta-tubulin or calmodulin genes, which are not available in most laboratories. Multiplex PCR assays or matrix-assisted laser desorption ionization - time-of-flight mass spectrometry (MALDI-TOF MS) gave promising results for rapid and accurate distinction between A. fumigatus and other Aspergillus spp. of the section Fumigati in clinical practice. Improved diagnostic procedures and antifungal susceptibility testing may be helpful for the early detection and management of these particular IA cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.